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Abstract
Objective
Betatrophin has been identified as a marker linking liver with beta cell function and lipid
metabolism in murine models. Until now, the regulation of circulating betatrophin in humans
is not entirely clear. We here analyzed the relation of betatrophin levels to phenotypes of the
metabolic syndrome and speculated that renal function might influence circulating betatro-
phin levels and explain age-dependent changes of betatrophin.
Subjects
We analyzed blood samples from 535 individuals participating in the Metabolic Syndrome
Berlin Potsdam study.
Results
In a crude analysis we found a positive correlation between betatrophin levels and HbA1c
(r = 0.24; p < 0.001), fasting glucose (r = 0.20; p < 0.001) and triglycerides (r = 0.12; p =
0.007). Furthermore betatrophin was positively correlated with age (r = 0.47; p <0.001), sys-
tolic blood pressure (r = 0.17; p < 0.001), intima media thickness (r = 0.26; p < 0.001) and
negatively correlated with CKD-EPI eGFR (r = -0.33; p < 0.001) as an estimate of renal func-
tion. Notably, eGFR remained highly associated with betatrophin after adjustment for age,
waist circumference, gender, HbA1c and lipid parameters in a multivariate linear regression
model (β = -0.197, p< 0.001).
Conclusions
Our data suggest that circulating levels of betatrophin depend on age, gender, waist circum-
ference, total/HDL cholesterol ratio and renal function. Especially the association to eGFR
highlights the importance for future studies to address renal function as possible influence
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Introduction
A recent report about a newly identified predominantly liver derived circulating factor
referred to as betatrophin attracted great attention because of its capability to promote beta
cell proliferation and improving glucose tolerance in mice [1]. Betatrophin also called
ANGPTL8, RIFL or Lipasin was initially identified in 2012. It is an atypical member of the
angiopoietin-like protein family (ANGPTLs) functionally considered as a nutritionally-depen-
dent blood lipid regulator [2–4] inhibiting the lipoprotein lipase and thereby regulating tri-
glyceride (TG) levels [5]. Subsequent studies analyzing the phenotype of betatrophin knock-
out animals challenged the perspective of betatrophin having a prominent role in glucose
metabolism. While knock-out animals showed clear signs of an altered lipid metabolism with
significantly lower TG levels in the fed state no changes in glucose homeostasis were observed
[6]. Nevertheless the identification of this liver derived circulating factor potentially involved
in the regulation of glucose and lipid metabolism triggered a great research interest in this hor-
mone as potential therapeutic target or new biomarker for the metabolic syndrome, leading to
several clinical studies examining the role of betatrophin in humans with multiple pathological
conditions. Most studies so far compared betatrophin levels between diabetic and non-diabetic
subjects (type 2 diabetes, type 1 diabetes and gestational diabetes), providing quite heteroge-
neous results. While the majority showed higher serum concentrations for diabetic patients
[7–9] others failed to detect any significant differences [10]or even showed decreased betatro-
phin levels for diabetic compared to non-diabetic individuals[11]. Based on the pre-clinical
data indicating that betatrophin is a nutrition dependent lipogenic factor, appearing as a
potential mediator of post-prandial fatty acid trafficking and storage to adipose tissue [4], a
number of clinical studies investigated the role of betatrophin in lipid metabolism showing
positive correlations with triglycerides [9, 12, 13]. Beyond that, the results of studies looking
for a putative link to obesity presented a similar heterogeneity as in diabetes, differing for beta-
trophin levels to be higher [14], lower [15] or equal [16] comparing patients with obesity to
lean individuals. Taking into consideration the partial contradictory results on the influence of
betatrophin on glucose and lipid metabolism as well as obesity, we analyzed the participants of
the Metabolic-Syndrome Berlin-Potsdam follow-up cohort with respect to their betatrophin
levels in relation to markers of the metabolic syndrome. We included intima media thickness
as a marker for atherosclerosis and CKD-EPI estimated GFR as a marker for renal function in
order to analyze two further age dependent phenotypes, given the situation that the majority
of clinical studies has pointed towards a strong positive correlation of betatrophin with age [8,
13, 17–19].
Material and methods
For this study blood samples of 535 individuals of the Metabolic Syndrome Berlin Potsdam
(MesyBePo) follow-up study were analyzed. Details of baseline phenotyping were described
previously [20]. The study protocol was approved by the ethics committees of the Landesa¨rzte-
kammer Brandenburg and the Freie Universita¨t Berlin. All study samples were taken at 8:00 a.
m. after an overnight fast. An oral glucose tolerance test (OGTT) was performed in all individ-
uals, and fasting blood samples were taken before OGTT. Patient classification with respect to
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PLOS ONE | DOI:10.1371/journal.pone.0173197 March 3, 2017 2 / 10
Gesellschaft (http://www.deutsche-diabetes-
gesellschaft.de/home.html) and the Deutsche
Forschungsgemeinschaft DFG KFO218 (http://
www.dfg.de/). The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
impaired glucose tolerance (IGT), impaired fasting glucose (IFG) and T2DM was made
according to either prior diagnosis of T2DM with accompanying antidiabetic medication or
based on the results of fasting glucose and 2h glucose levels after GTT according to the official
WHO diagnostic criteria [21]. EDTA and citrate plasma as well as serum was taken from par-
ticipants. Plasma was placed on ice and spun down within 30 min at 4˚C. After centrifugation,
the plasma was immediately transferred to a −20˚C freezer. Within the next 24 h, all samples
were transferred on dry ice to a −80˚C freezer, where aliquots were stored until assay. Serum
was left at room temperature for 30 min to allow clotting, thereafter, the sample was centri-
fuged. The serum was then transferred to a −20˚C freezer and within 24 h to a −80˚C freezer,
comparable to all plasma samples. Betatrophin levels were measured by validated enzyme-
linked immunosorbent assay (ELISA) kit provided by EIAAB (Catalogue number E1164H;
Wuhan, China). The internal quality control revealed an intra-assay coefficient of variability of
5.2% and an inter-assay CoV of 13.6% for the measured full-length betatrophin levels in plasma
samples. Carotid arterial IMT was measured at the posterior wall of the common carotid artery
at three different positions using a high resolution ultrasound (Kretz AG, Germany). Mean and
maximum values for IMT, which included possible plaques, were calculated. CKD-EPI esti-
mated glomerular filtration rate was calculated according to the established mathematical for-
mula from the Chronic Kidney Disease Epidemiology Collaboration [22].The study was carried
out in accordance with the recommendations of the Declaration of Helsinki, and the experi-
mental protocol of the study was approved by the institutional ethical committee. All subjects
gave written informed consent. Statistical calculations were performed using SPSS 22.0 software
(IBM Statistics, Germany). All values are presented as mean and SEM, if not otherwise men-
tioned. Logarithmic transformation of betatrophin levels was performed to achieve normal dis-
tribution tested by visual inspection and Shapiro Wilk test. The statistical tests in general were
performed with ln(betatrophin) values. To provide a better comparability and understanding
non-transformed values were depicted when absolute plasma concentration were presented.
One-way ANOVA was performed followed by post-hoc Bonferroni test. A value of p< 0.05
was considered as statistically significant. Pearson Correlation coefficients were analyzed with
respect to log Betatrophin. Multivariate linear regression models were calculated to identify
independent relations between Betatrophin and ageing, renal function and multiple markers of
the metabolic syndrome. Three models were calculated: crude without adjustment, model 1 was
adjusted for age and sex only and model 2 was additionally adjusted for waist circumference,
systolic blood pressure, HbA1c, total cholesterol/HDL cholesterol ratio, triglycerides and smok-
ing (fully adjusted model).
Results
Betatrophin levels were analyzed in participants of the MesyBePo study follow-up cohort
(Metabolic Syndrome Berlin-Potsdam) that included healthy control subjects as well as
patients with impaired glucose metabolism including overt type 2 diabetes. Baseline Character-
istics of the study cohort are summarized in Table 1.
In a crude analysis (Table 2) with respect to different markers of the metabolic syndrome,
we found a strong positive correlation of serum betatrophin concentrations with age (r = 0.47;
p<0.001) as it has been described previously 8, 13, 17–19. Furthermore serum levels of betatro-
phin were positively correlated to markers of glucose metabolism HbA1c (r = 0.24; p< 0.001)
as well as fasting glucose levels (r = 0.20; p< 0.001) and serum glucose concentration 2h after
performing a standard oral glucose tolerance test (r = 0.15; p< 0.001). In accordance calcu-
lated indices for insulin sensitivity HOMA-IR (r = 0.19; p< 0.001) and QUICKI (r = -0.14,
p = 0.001) showed similar associations. Comparing the different subgroups of our cohort with
Betatrophin and eGFR
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respect to an altered glucose metabolism, we see the same constellation as it has been previ-
ously published [7, 13, 18]. We found participants with diabetes having significantly higher
betatrophin levels than individuals having a normal glucose metabolism, with no significant
differences for people with an impaired fasting glucose (IFG), impaired glucose tolerance
(IGT) or both (IFG+IGT) compared to controls (One-way ANOVA p< 0.001; mean betatro-
phin concentration: controls = 506.4 pg/ml, IFG = 601.1 pg/ml (p = 0.42), IGT = 554.6 pg/ml
(p = 1.0), IFG+IGT = 643.2 pg/ml (p = 0.873), type 2 diabetes 659.9 pg/ml (p< 0.001)). In
our study we found no correlations with parameters of cholesterol metabolism, total choles-
terol (r = -0.01; p = 0.83), LDL cholesterol (r = -0.06; p = 0.191) or HDL cholesterol (r = -0.02;
p = 0.636) but a positive correlation with triglyceride levels (r = 0.12; p = 0.007). With respect
to obesity we found a positive correlation of betatrophin with waist circumference (r = 0.23;
p< 0.010) and with participants body mass index (r = 0.12; p = 0.008). Interestingly we found
a distinct negative correlation of betatrophin with CKD-EPI eGFR (r = -0.33; p< 0.001). The
majority of participants from the MeSyBePo cohort showed a normal to moderately decreased
renal function (GFR category 1 |> 90ml/min: 27.8%, GFR category 2 | 60–89 ml/min: 63.1%,
GFR category 3 | 30–59 ml/min: 6.0%). In correspondence to the mentioned association the
Table 1. Baseline characteristics of the MesyBePo Cohort (N = 535) with respect to the included mark-
ers of the metabolic syndrome.
Baseline Characteristics
N = 535 S.E.M.
Male 151 (28.2%)
Female 384 (71.8%)
Age (years) 55.6 ± 0.49
Hypertension 179 (33.5%)
Blood Pressure systolic (mmHg) 126.5 ± 0.74
Blood Pressure diastolic (mmHg) 78.4 ± 0.42
Smoking 45 (8.4%)
Coronary Heart Disease 19 (3.6%)
Intima Media Thickness (mm) 0.73 ± 0.01
Overweight 418 (78.1%)
Body Mass Index 29.6 ± 0.26
Waist Circumference (cm) 96.4 ± 0.59
Dyslipoproteinemia 113 (21.1%)
Cholesterol (mmol/l) 5.53 ± 0.04
HDL (mmol/l) 1.43 ± 0.02
LDL (mmol/l) 3.45 ± 0.04
Triglycerides (mmol/l) 1.45 ± 0.03
Type 2 Diabetes 32 (6.0%)
HbA1c (%) 5.5 ± 0.03
HbA1c (mmol/mol) 37.1 ± 0.30
Fasting Glucose (mg/dl) 98 ± 0.95
Glucose 2h after oGTT (mg/dl) 120 ± 2.02
ASAT (IU/l) 26.1 ± 0.46
ALAT (IU/L) 19.4 ± 0.46
GGT (IU/L) 26.0 ± 0.68
Creatinine (mg/dl) 0.89 ± 0.01
CKD-EPI eGFR (ml/min) 81.2 ± 0.68
Betatrophin (pg/ml) 543.1 ± 10.5
doi:10.1371/journal.pone.0173197.t001
Betatrophin and eGFR
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comparison of betatrophin levels with respect to the usual GFR categories revealed significant
differences between each standard GFR category with the highest betatrophin level in the bot-
tom GFR group: Betatrophin—GFR category 1: 469.3 pg/ml (S.E.M. 16.3), GFR category 2:
550.4 pg/ml (S.E.M. 11.3), GFR category 3: 799.0 pg/ml (S.E.M. 79.5), p< 0.001. Since no
patients with an eGFR < 30 ml/min participated in our study, we are unfortunately not able to
address the role of betatrophin in patients with a severely impaired renal function. Addition-
ally intima media thickness as marker for arteriosclerosis showed a positive correlation with
betatrophin (r = 0.26; p< 0.001) as well systolic blood pressure (r = 0.17; p< 0.001). The posi-
tive correlation of betatrophin (β = 0.261, p< 0.001) with the intima media thickness was not
found when adjusting for age, sex and cardiovascular risk factors.
Notably the negative correlation for renal function remained associated with betatrophin
(β = -0.197, p< 0.001) after adjustment for age, gender, abdominal obesity and standard
parameters of lipid and glucose metabolism in a multivariate linear regression model
(Table 3).
Conclusion
The initial hope to use betatrophin as drug therapy target for diabetec patients following the
discovery that it was potentially able to promote beta-cell proliferation in mice[1] has not been
fulfilled so far. On one hand subsequent preclinical studies examining the effects of deletion as
well as overexpression of betatrophin showed no evidence for a prominent isolated role of
betatrophin in controlling beta-cell proliferation[23, 24]. On the other hand the clinical evalua-
tion of betatrophin in humans yielded a quite heterogeneous pattern with partially contradic-
tory results [11, 18, 25, 26]. The recent retraction of the initial paper describing betatrophin as
potential beta cell mitogen [27] and the collected data from clinical studies largely invalidate
the perspective of a clinically relevant player in beta cell proliferation. Nevertheless the so far
accumulating data on betatrophin suggest a more intermingled role in metabolic function
Table 2. Correlation coefficients and corresponding p-values.
Correlations ln Betatrophin
Variable R p-value
Age 0.469 < 0.001
Intima Media Thickness 0.261 < 0.001
CKD-EPI eGFR -0.329 < 0.001
Creatinine 0.277 < 0.001
Systolic Blood Pressure 0.171 < 0.001
Diastolic Blood Pressure 0.014 0.758
BMI 0.115 0.008
Waist Circumference 0.227 < 0.001
Total Cholesterol -0.009 0.830
LDL Cholesterol -0.057 0.191
HDL Cholesterol -0.021 0.636
Triglycerides 0.116 0.007
HbA1c 0.235 < 0.001
Fasting Glucose 0.200 < 0.001
Glucose 2h after OGTT 0.150 0.001
ASAT 0.064 0.141
ALAT 0.055 0.205
Smoking 0.073 0.093
doi:10.1371/journal.pone.0173197.t002
Betatrophin and eGFR
PLOS ONE | DOI:10.1371/journal.pone.0173197 March 3, 2017 5 / 10
potentially involving the cross talk of lipid and glucose regulation [28]. In our analysis we
found betatrophin to be positively correlated to HbA1c, fasting blood glucose and triglyceride
levels as well as BMI and waist circumference. This is in line with the majority of the so far
published clinical studies. One important aspect addressing the divergent results for betatro-
phin in humans might be the use of different ELISA kits for detecting circulating betatrophin
levels. In this analysis we used the commercially available ELISA kit provided by EIAAB (Cata-
logue number E1164H; Wuhan, China) which is based on an antibody recognizing the N-ter-
minus and is the most commonly used detection method so far [8, 13, 17, 19, 25, 29, 30]. A
recent report compared this ELISA kit to a second commonly used kit from Phoenix Pharma-
ceuticals (Catalogue number EK-051-55; Burlingame, CA, USA) that is based on an antibody
against the C-terminus [31]. While both assays adequately recognized human recombinant
betatrophin the results indicate that betatrophin undergoes proteolytic regulation releasing the
C-terminal fragments. As consequence the different ELISAs measure either full-length beta-
trophin only or full-length protein and C-terminal fragment. It is currently not known if either
full-length betatrophin or the C-terminal fragment is responsible for the biological effect nor
what further processes are involved in betatrophin degradation and clearance. Nevertheless
this discrepancy may in part explain the largely diverse results of the clinical studies conducted
so far. Numerous different ELISA kits with variable technical properties for detecting the differ-
ent protein subsets have been used for the analysis of the published clinical data. This aspect
points out particularly that great caution is advised for the interpretation and comparison of
betatrophin levels and the proteins potential relevance in metabolic regulation. We recently
published a study on a potential role of betatrophin in the postprandial switch from lipid to glu-
cose metabolism showing that the impaired betatrophin response in obese subjects is restored
after weight loss to a degree comparable to lean individuals [28]. For this trial we used the same
ELISA kit for detecting betatrophin further prompting the notion of the full length protein
might be the active form of betatrophin. Given betatrophin’s putative dual role in lipid and glu-
cose metabolism as well as its correlation with ageing and in some studies towards an athero-
genic cholesterol profile [25, 30], it is tempting to investigate a possible influence on markers
of arteriosclerosis. In our study we see no correlation of betatrophin with total, LDL or HDL
cholesterol but a positive correlation with systolic blood pressure and intima media thickness.
These associations were only detectable in the crude analysis and disappeared when adjusting
for age and gender making an independent betatrophin effect less likely. Interestingly, even
Table 3. Linear regression for Betatrophin in the fully adjusted model with representation of significant standardized beta value.
ln Betatrophin
Parameter Correlation Standardized Beta Correlation x Standardized Beta x 100 p-Value
Age 0.301 0.322 9.70 < 0.001
CKD-EPI eGFR -0.194 -0.197 3.81 < 0.001
Gender -0.157 -0.150 2.34 < 0.001
Waist Circumference 0.123 0.121 1.49 0.006
Total/HDL Cholesterol Ratio -0.095 -0.096 0.91 0.033
HbA1c 0.071 0.066 0.47 0.112
Triglycerides 0.055 0.056 0.31 0.217
Systolic Blood Pressure -0.028 -0.027 0.07 0.533
Smoking 0.001 0.001 0.00 0.986
Total 19.11 < 0.001
The multiplicative term (Correlation x Standardized β x100) explains the variation of betatrophin explained by the respective parameter in percent.
doi:10.1371/journal.pone.0173197.t003
Betatrophin and eGFR
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after fully adjusting for cardiovascular risk factors age, gender, waist circumference, total/HDL
cholesterol ratio and renal function remain significantly correlated with betatrophin. Similar to
the above mentioned results correlations of betatrophin and age can be found in recent clinical
studies to be either positive [18, 19] or negative [32]. With respect to sex specific differences
betatrophin levels have been described to be significantly higher in males [16] as well as in
females [11]. Besides differences in detection methods other factors might be responsible for the
discrepancies. The results come from different study populations differing largely in age, ethnic-
ity, basic disease state and medication. In our cohort adjusting for the intake of antihyperten-
sive, lipid lowering or antidiabetic medication has no substantial impact on the described
associations while only antidiabetic drug treatment exerts in independent influence in the fully
adjusted model (std. ß = 0.143, p = 0.001). Given the low prevalence of antidiabetic drug treat-
ment (2.8% of all participants) it remains elusive if a distinct pharmacological influence on beta-
trophin need to be taken into account in general. Notably, data on a possible influence of renal
function on circulating betatrophin levels are sparse, taking into consideration that study popu-
lations were varying largely by age and are affected by different manifestations of the metabolic
syndrome that predispose for an impaired renal function. Some smaller studies identified weak
positive correlations with serum creatinine levels not reaching statistical significance [8, 13, 32].
One recent Japanese study in diabetic patients found a significant negative correlation of beta-
trophin and creatinine clearance as well as eGFR (calculation adjusted for Japanese population)
that seemed mainly driven by a common association of the two factors with age [19]. In slight
contrast a recent German study, analyzing betatrophin levels in diabetic patients undergoing
hemodialysis compared to diabetic individuals with sustained renal function, found a significant
positive correlation of betatrophin and eGFR [33]. In this study patients on hemodialysis had
significantly lower betatrophin levels compared with subjects having an eGFR> 50ml/min/
1,73m2. A finding that may argue against a possible renal elimination of betatrophin, that has
been the initial hypothesis of the authors. Furthermore a third recent study from Taiwan inves-
tigated the correlation of full-length betatrophin with urinary albumin excretion and eGFR as
markers of diabetic nephropathy in patients suffering from type 2 diabetes. They found serum
betatrophin levels to be higher in patients with macroalbuminuria compared to normoalbumi-
nuria with an independent inverse association to eGFR and speculate betatrophin to be a novel
endocrine regulator involved in the progression of diabetic nephropathy [34]. Unfortunately
our data acquisition did not include albumin excretion in 24h urine nor urine creatinine levels.
Solemnly albumin concentration in the spot urine was measured and didn’t reveal a significant
correlation with betatrophin. Given the low prevalence of elevated urinary albumin excretion in
our cohort (albumin concentration < 20 mg/l: 86.0%; albumin concentration 20–200 mg/l:
13.3%; albumin concentration > 200 mg/l: 0.7%), we cannot properly address the aspect of an
association between betatrophin and urinary albumin excretion or albumin/creatinine ratio as
additional markers for kidney function. Nevertheless in the study by Chen et. al. elevated beta-
trophin levels in type 2 diabetes have been found to be associated with impaired renal function
and also with urinary albumin excretion. The same detection method for full-length betatro-
phin has been applied there and the findings have been interpreted as potential link of betatro-
phin function with respect to lipid metabolism and the progression of diabetic nephropathy. In
our own cohort consisting of 535 patients from the MesyBePo follow-up study with a normal to
mildly impaired renal function (average eGFR of 81.2 ml/min at an average of 55.6 years; 6% of
participants diagnosed with diabetes) betatrophin showed a similarly strong independent corre-
lation of circulating hormone levels and renal function. Interestingly for other members of the
angiopoietin-like protein family such as ANGPTL3, on which betatrophin has a regulatory
effect by promoting ANGPTL3 cleavage, a higher serum concentration in patients with kidney
disease has been described [35]. The same phenomenon of elevated blood concentrations in
Betatrophin and eGFR
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patients with impaired renal function has been documented for a number of other hepatokines
and adipokines e.g. FGF21 [36], chemerin [37] and leptin [38]. Taken together circulating beta-
trophin levels are independently associated with renal function. Our study further extends the
data on betatrophin’s potential role in diabetic nephropathy in terms of linking betatrophin to
renal function even in absence of a decisive renal pathology. At this point it remains an open
question if betatrophin exerts an effect on kidney function or the progression of a pre-existing
nephropathy or if wise versa betatrophin turnover depends on renal function. Further experi-
ments are needed to elucidate physiological significance of this finding and future studies on
betatrophin should take a possible influence of renal function into special account.
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